William Hicks, MD
Internal Medicine · Mobile, ALNPI 1235161092
Payments from drug & device makers
Across 442 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$808
- Novartis$805
- AbbVie$646
- Bayer$641
- Johnson & Johnson$545
- Lilly USA, LLC$440
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,986100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $808 |
| Novartis | 49 | $805 |
| AbbVie(2 entities) | 39 | $646 |
| Bayer | 36 | $641 |
| Johnson & Johnson | 38 | $545 |
| Lilly USA, LLC | 27 | $440 |
| AstraZeneca | 27 | $415 |
| GSK | 26 | $374 |
| Pfizer | 27 | $359 |
| Boehringer Ingelheim | 18 | $291 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $283 |
| Daiichi Sankyo Inc. | 12 | $175 |
| Amgen | 12 | $172 |
| Sumitomo Pharma America, Inc. | 9 | $145 |
| Sanofi-aventis U.S. LLC | 7 | $121 |
| Antares Pharma, Inc. | 3 | $98 |
| Sunovion Pharmaceuticals Inc. | 5 | $82 |
| Amarin Pharma, Inc. | 3 | $59 |
| Merck | 4 | $53 |
| Esperion Therapeutics, Inc. | 4 | $52 |
| Eisai Inc. | 3 | $48 |
| Astellas Pharma US Inc | 3 | $48 |
| Galt Pharmaceuticals, LLC | 1 | $46 |
| Corcept Therapeutics | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$7,013 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 153 | $185,340 |
| EliquisApixaban | 124 | $130,899 |
| JanuviaSitagliptin Phosphate | 100 | $123,240 |
| OzempicSemaglutide | 93 | $107,482 |
| MounjaroTirzepatide | 60 | $79,867 |
| XifaxanRifaximin | 15 | $47,353 |
| LinzessLinaclotide | 57 | $47,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $43,219 |
| XareltoRivaroxaban | 44 | $40,181 |
| FarxigaDapagliflozin Propanediol | 28 | $35,607 |
| TrulicityDulaglutide | 21 | $34,425 |
| EntrestoSacubitril/Valsartan | 32 | $27,608 |
| MyrbetriqMirabegron | 24 | $23,483 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $20,042 |
| NexletolBempedoic Acid | 11 | $13,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $291 | $185,340153 claims |
| MerckJanuvia, Janumet Xr | $53 | $143,282118 claims |
| PfizerEliquis | $359 | $130,899124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $440 | $114,29281 claims |
| Novo NordiskOzempic | $808 | $107,48293 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $374 | $56,95988 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $283 | $47,35315 claims |
| AbbVieLinzess | $646 | $47,30957 claims |
| Johnson & JohnsonXarelto | $545 | $40,18144 claims |
| AstraZenecaFarxiga, Symbicort | $415 | $39,68441 claims |
| NovartisEntresto | $805 | $27,60832 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $23,48324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Mobile
- Harry StuddardMobile$12.9M
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Bobby WrightsMobile$89K
- Rahel AzizMobile$67K
- Jamie CaudillMobile$52K
- Thomas GarthMobile$48K
- Lin LiMobile$45K
- Edward CarlosMobile$26K
- Donald SandersMobile$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.